Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil
Abstract INTRODUCTION: In 2013, combination therapy using peginterferon, ribavirin, and boceprevir or telaprevir was introduced to treat hepatitis C virus genotype 1 infection in Brazil. The effectiveness of this therapy in four Brazilian regions was evaluated. METHODS: Clinical and virological data...
Published in: | Revista da Sociedade Brasileira de Medicina Tropical |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Sociedade Brasileira de Medicina Tropical (SBMT)
|
Subjects: | |
Online Access: | https://doi.org/10.1590/0037-8682-0279-2017 https://doaj.org/article/c9689d0626c24242b3e598edfbc61171 |
id |
ftdoajarticles:oai:doaj.org/article:c9689d0626c24242b3e598edfbc61171 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:c9689d0626c24242b3e598edfbc61171 2023-05-15T15:12:18+02:00 Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil Cirley Maria de Oliveira Lobato Natalia Balassiano Elodie Bomfim Hyppolito Rafaela Liz Pellegrim Sanchez-Lermen Izabelle Venturini Signorelli Miguel Yasuo Tomita Nicacio Alberto Pereira Firmino Filho Thais Guaraná de Andrade José Milton de Castro Lima Talita Amorim de Arruda Fernanda Schwanz Coutinho Everton Felipe do Vale Araujo Ticiana Mota Esmeraldo Erlon Cortez Rafaela Lorenzon Aragão Capeli Melquior Brunno Mateus de Matos Francisco Sérgio Rangel Pessoa Hélder Cássio de Oliveira Érico Antônio Gomes de Arruda Patrícia Lofêgo Gonçalves Antônio Haroldo Araújo Filho Eliane Bordalo Cathalá Esberard Francisco José Dutra Souto https://doi.org/10.1590/0037-8682-0279-2017 https://doaj.org/article/c9689d0626c24242b3e598edfbc61171 EN eng Sociedade Brasileira de Medicina Tropical (SBMT) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000100014&lng=en&tlng=en https://doaj.org/toc/1678-9849 1678-9849 doi:10.1590/0037-8682-0279-2017 https://doaj.org/article/c9689d0626c24242b3e598edfbc61171 Revista da Sociedade Brasileira de Medicina Tropical, Vol 51, Iss 1, Pp 14-20 Hepatitis C vírus Sustained virological response Telaprevir Boceprevir Post-marketing surveillance Arctic medicine. Tropical medicine RC955-962 article ftdoajarticles https://doi.org/10.1590/0037-8682-0279-2017 2022-12-31T02:57:30Z Abstract INTRODUCTION: In 2013, combination therapy using peginterferon, ribavirin, and boceprevir or telaprevir was introduced to treat hepatitis C virus genotype 1 infection in Brazil. The effectiveness of this therapy in four Brazilian regions was evaluated. METHODS: Clinical and virological data were obtained from patients of public health institutions in five cities, including sustained virological response (SVR) and side effects. Patients with advanced fibrosis (F3/4), moderate fibrosis (F2) for > 3 years, or extra-hepatic manifestations were treated according to Ministry of Health protocol. Treatment effectiveness was verified by using bivariate and multivariate analysis; p-values of < 0.05 were considered significant. RESULTS: Of 275 patients (64.7% men; average age, 57 years old), most (61.8%) were treatment-experienced; 53.9% had subgenotype 1a infection, 85.1% had advanced fibrosis, and 85.5% were treated with telaprevir. SVR was observed in 54.2%. Rapid virological response (RVR) was observed in 54.6% of patients (data available for 251 patients). Overall, 87.5% reported side effects and 42.5% did not complete treatment. Skin rash, severe infection, and death occurred in 17.8%, 2.5%, and death in 1.4% of cases, respectively. SVR was associated with treatment completion, RVR, and anemia. CONCLUSIONS: The effectiveness of hepatitis C virus triple therapy was lower than that reported in phase III clinical trials, possibly owing to the prioritized treatment of patients with advanced liver fibrosis. The high frequency of side effects and treatment interruptions observed supported the decision of the Brazilian authorities to suspend its use when safer and more effective drugs became available in 2015. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Revista da Sociedade Brasileira de Medicina Tropical 51 1 14 20 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Hepatitis C vírus Sustained virological response Telaprevir Boceprevir Post-marketing surveillance Arctic medicine. Tropical medicine RC955-962 |
spellingShingle |
Hepatitis C vírus Sustained virological response Telaprevir Boceprevir Post-marketing surveillance Arctic medicine. Tropical medicine RC955-962 Cirley Maria de Oliveira Lobato Natalia Balassiano Elodie Bomfim Hyppolito Rafaela Liz Pellegrim Sanchez-Lermen Izabelle Venturini Signorelli Miguel Yasuo Tomita Nicacio Alberto Pereira Firmino Filho Thais Guaraná de Andrade José Milton de Castro Lima Talita Amorim de Arruda Fernanda Schwanz Coutinho Everton Felipe do Vale Araujo Ticiana Mota Esmeraldo Erlon Cortez Rafaela Lorenzon Aragão Capeli Melquior Brunno Mateus de Matos Francisco Sérgio Rangel Pessoa Hélder Cássio de Oliveira Érico Antônio Gomes de Arruda Patrícia Lofêgo Gonçalves Antônio Haroldo Araújo Filho Eliane Bordalo Cathalá Esberard Francisco José Dutra Souto Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil |
topic_facet |
Hepatitis C vírus Sustained virological response Telaprevir Boceprevir Post-marketing surveillance Arctic medicine. Tropical medicine RC955-962 |
description |
Abstract INTRODUCTION: In 2013, combination therapy using peginterferon, ribavirin, and boceprevir or telaprevir was introduced to treat hepatitis C virus genotype 1 infection in Brazil. The effectiveness of this therapy in four Brazilian regions was evaluated. METHODS: Clinical and virological data were obtained from patients of public health institutions in five cities, including sustained virological response (SVR) and side effects. Patients with advanced fibrosis (F3/4), moderate fibrosis (F2) for > 3 years, or extra-hepatic manifestations were treated according to Ministry of Health protocol. Treatment effectiveness was verified by using bivariate and multivariate analysis; p-values of < 0.05 were considered significant. RESULTS: Of 275 patients (64.7% men; average age, 57 years old), most (61.8%) were treatment-experienced; 53.9% had subgenotype 1a infection, 85.1% had advanced fibrosis, and 85.5% were treated with telaprevir. SVR was observed in 54.2%. Rapid virological response (RVR) was observed in 54.6% of patients (data available for 251 patients). Overall, 87.5% reported side effects and 42.5% did not complete treatment. Skin rash, severe infection, and death occurred in 17.8%, 2.5%, and death in 1.4% of cases, respectively. SVR was associated with treatment completion, RVR, and anemia. CONCLUSIONS: The effectiveness of hepatitis C virus triple therapy was lower than that reported in phase III clinical trials, possibly owing to the prioritized treatment of patients with advanced liver fibrosis. The high frequency of side effects and treatment interruptions observed supported the decision of the Brazilian authorities to suspend its use when safer and more effective drugs became available in 2015. |
format |
Article in Journal/Newspaper |
author |
Cirley Maria de Oliveira Lobato Natalia Balassiano Elodie Bomfim Hyppolito Rafaela Liz Pellegrim Sanchez-Lermen Izabelle Venturini Signorelli Miguel Yasuo Tomita Nicacio Alberto Pereira Firmino Filho Thais Guaraná de Andrade José Milton de Castro Lima Talita Amorim de Arruda Fernanda Schwanz Coutinho Everton Felipe do Vale Araujo Ticiana Mota Esmeraldo Erlon Cortez Rafaela Lorenzon Aragão Capeli Melquior Brunno Mateus de Matos Francisco Sérgio Rangel Pessoa Hélder Cássio de Oliveira Érico Antônio Gomes de Arruda Patrícia Lofêgo Gonçalves Antônio Haroldo Araújo Filho Eliane Bordalo Cathalá Esberard Francisco José Dutra Souto |
author_facet |
Cirley Maria de Oliveira Lobato Natalia Balassiano Elodie Bomfim Hyppolito Rafaela Liz Pellegrim Sanchez-Lermen Izabelle Venturini Signorelli Miguel Yasuo Tomita Nicacio Alberto Pereira Firmino Filho Thais Guaraná de Andrade José Milton de Castro Lima Talita Amorim de Arruda Fernanda Schwanz Coutinho Everton Felipe do Vale Araujo Ticiana Mota Esmeraldo Erlon Cortez Rafaela Lorenzon Aragão Capeli Melquior Brunno Mateus de Matos Francisco Sérgio Rangel Pessoa Hélder Cássio de Oliveira Érico Antônio Gomes de Arruda Patrícia Lofêgo Gonçalves Antônio Haroldo Araújo Filho Eliane Bordalo Cathalá Esberard Francisco José Dutra Souto |
author_sort |
Cirley Maria de Oliveira Lobato |
title |
Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil |
title_short |
Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil |
title_full |
Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil |
title_fullStr |
Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil |
title_full_unstemmed |
Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil |
title_sort |
effectiveness of first-wave protease inhibitors in hepatitis c virus genotype 1 infection: a multicenter study in brazil |
publisher |
Sociedade Brasileira de Medicina Tropical (SBMT) |
url |
https://doi.org/10.1590/0037-8682-0279-2017 https://doaj.org/article/c9689d0626c24242b3e598edfbc61171 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Revista da Sociedade Brasileira de Medicina Tropical, Vol 51, Iss 1, Pp 14-20 |
op_relation |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000100014&lng=en&tlng=en https://doaj.org/toc/1678-9849 1678-9849 doi:10.1590/0037-8682-0279-2017 https://doaj.org/article/c9689d0626c24242b3e598edfbc61171 |
op_doi |
https://doi.org/10.1590/0037-8682-0279-2017 |
container_title |
Revista da Sociedade Brasileira de Medicina Tropical |
container_volume |
51 |
container_issue |
1 |
container_start_page |
14 |
op_container_end_page |
20 |
_version_ |
1766343000278958080 |